Agios Pharma (AGIO) Misses Q3 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Agios Reports Third Quarter 2016 Financial Results and Reviews Recent Progress in IDH and PKR Development Programs
November 3, 2016 7:01 AM EDT Enasidenib (AG-221) on Track for NDA Submission in IDH2m Positive Relapsed/Refractory AML by Year End  Â
                         Follow-on Offering Raised Approximately $173 Million in September; Updated 2016 Year End Cash Position Expected to be More than $550 Million                           Seven Abstracts Accepted for Presentation at ASH, Including Updated Data from AG-348 Phase 2 DRIVE PK, AG-519 Phase 1 Healthy Volunteer and AG-120 Phase 1 Dose Escalation Studies                          Â
CAMBRIDGE, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today reported business highlights and... More
